Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to check the T and B cells of the immune system in 50 newly
transplanted patients whom have received a kidney (50 recipients and 50 donors totaling 100
anticipated participants). This will be done to see how the Standard of Care (SOC)
anti-rejection medication, Alemtuzumab (Campath 1-H®) affects these cells- Campath 1-H®
reduces the number of T cells produced by one's body.